Skip to main content

Impact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.

Suganuma N, Matsubara Y, Takahashi A, Yamanaka T, Yamashita T, Saito A, Kawachi K, Yokose T, Narimatsu H, Hoshino D, Miyagi Y, Yoshioka E

Publication: Anticancer Res (2024) • Vol 44 • Page 5225-5230PMID: 39626910View on PubMed

Purpose

This paper investigated the effects of warm ischemia time (time from surgical clamping to removal of the specimen from the body), cold ischemia time (time from specimen removal from the body to fixation) and fixation duration on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) staining by comparing case-matched breast cancer preoperative biopsy and surgical resection specimens that differed in staining within the context of warm ischemia time (≤30 min versus >30 min or ≤60 min versus >60 min), cold ischemia time (≤1 h or > 1 h) and fixation duration (6-72 h versus <6 h or >72 h).  

Conclusion

For surgical resection specimens, the median warm ischemia time was 23 min (range=3-116 min), cold ischemia time was 37 min (range=20-1,052 min), and fixation duration was 43 h (range=17-115 h). Importantly, 91.7% (254 of 277) of surgically resected specimens had a cold ischemia time of ≤1 h, as recommended by the ASCO/CAP guidelines, and 94.9% (263 of 277) of specimens were fixed for 6-72 h, as recommended by the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Non-significant trends toward a greater decrease in ER, PR and HER-2 immunostaining relative to the matched biopsy specimen were identified for the 21 resection specimens with a cold ischemia of >1 h compared to those with a cold ischemia duration of ≤1 h. For the duration of fixation, the differences in staining for all three markers between case-matched biopsy and resection specimens were similar for the 263 specimens fixed for 6-72 h and the 14 specimens that were fixed for <6 or >72 h. While no significant effect of warm ischemia time was observed for ER and PR staining, HER-2 staining significantly increased relative to the case-matched biopsy specimen in the 86 specimens with a warm ischemia time >30 min relative to the 191 specimens with a warm ischemia time ≤30 min (P=0.012) and in the 21 specimens with a warm ischemia time >60 min relative to the 256 specimens with a warm ischemia time ≤60 min (P=0.043). HER-2 concordance rates for case-matched biopsy and resection specimens were comparable for the 91 resection specimens with warm ischemia times >30 min and the entire group of 277 cases  (65.1% or 53 of 91 cases versus 62.8% or 174 of 277 cases), but the percentage of specimens that had a higher score in the resection specimen was larger when warm ischemia time was >30 min (30.8% or 28 of 91 cases versus 23.8% or 66 of 277), and the percentage specimens that had a lower score in the resection specimen was slightly smaller when the warm ischemia time was >30 min  (11.0% or 10/91 cases versus 13.4% or 37 of 277).  While warm ischemia did not significantly affect HER-2 positivity (defined as a HER-2 staining score of 3+ or a HER-2 staining score of 2+ with ISH staining), 17 of the 27 HER-2 negative biopsies had low levels of HER-2 staining in the resection specimen (15 were 1+ and 2 were 2+), which the authors state might alter clinical decision making.

Studies (1)

Purpose

This study investigated the effects of warm ischemia time (time from surgical clamping to removal of the specimen from the body), cold ischemia time (time from specimen removal from the body to fixation) and fixation duration on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) staining by comparing case-matched breast cancer preoperative biopsy and surgical resection specimens that differed in staining within the context of warm ischemia time (≤30 min versus >30 min or ≤60 min versus >60 min), cold ischemia time (≤1 h or > 1 h) and fixation duration (6-72 h versus <6 h or >72 h). Paired preoperative biopsy and resection specimens were collected at the same center between May 2018 and April 2019 from 277 patients (274 women and 3 men) undergoing mastectomy (50 patients), breast conserving mastectomy (224 patients), or nipple-sparing mastectomy (3 patients) for breast cancer. Data regarding the warm ischemia time, cold ischemia time, and fixation time were recorded.  All specimens were fixed and stained for ER, PR and HER-2 in accordance with ASCO/CAP guidelines (details not provided). ER and PR staining were scored as a percentage of positive cells. HER-2 staining was scored on a scale of 0 to 3+ based on ASCO/CAP guidelines. Differences in ER, PR and HER-2 staining between matched biopsy and resection specimens and multiple linear regression models were constructed in R to account for warm ischemia time, cold ischemia time, and fixation duration.

Summary of Findings

For surgical resection specimens, the median warm ischemia time was 23 min (range=3-116 min), cold ischemia time was 37 min (range=20-1,052 min), and fixation duration was 43 h (range=17-115 h). Importantly, 91.7% (254 of 277) of surgically resected specimens had a cold ischemia time of ≤1 h, as recommended by the ASCO/CAP guidelines, and 94.9% (263 of 277) of specimens were fixed for 6-72 h, as recommended by the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Non-significant trends toward a greater decrease in ER, PR and HER-2 immunostaining relative to the matched biopsy specimen were identified for the 21 resection specimens with a cold ischemia of >1 h compared to those with a cold ischemia duration of ≤1 h. For the duration of fixation, the differences in staining for all three markers between case-matched biopsy and resection specimens were similar for the 263 specimens fixed for 6-72 h and the 14 specimens that were fixed for <6 or >72 h. While no significant effect of warm ischemia time was observed for ER and PR staining, HER-2 staining significantly increased relative to the case-matched biopsy specimen in the 86 specimens with a warm ischemia time >30 min relative to the 191 specimens with a warm ischemia time ≤30 min (P=0.012) and in the 21 specimens with a warm ischemia time >60 min relative to the 256 specimens with a warm ischemia time ≤60 min (P=0.043). HER-2 concordance rates for case-matched biopsy and resection specimens were comparable for the 91 resection specimens with warm ischemia times >30 min and the entire group of 277 cases  (65.1% or 53 of 91 cases versus 62.8% or 174 of 277 cases), but the percentage of specimens that had a higher score in the resection specimen was larger when warm ischemia time was >30 min (30.8% or 28 of 91 cases versus 23.8% or 66 of 277), and the percentage specimens that had a lower score in the resection specimen was slightly smaller when the warm ischemia time was >30 min  (11.0% or 10/91 cases versus 13.4% or 37 of 277).  While warm ischemia did not significantly affect HER-2 positivity (defined as a HER-2 staining score of 3+ or a HER-2 staining score of 2+ with ISH staining), 17 of the 27 HER-2 negative biopsies had low levels of HER-2 staining in the resection specimen (15 were 1+ and 2 were 2+), which the authors state might alter clinical decision making.

  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionWarm ischemia time
    >30 min
    >60 min
    ≤30 min
    ≤60 min
    Biospecimen AcquisitionCold ischemia time
    >1h
    ≤1h
    Biospecimen PreservationTime in fixative
    6-72 h
    <6 h or >72 h
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER-2
    PR